(3-methyl-4-oxo-4H-[1]naphthylidenaminooxy)-acetic acid | 6146-99-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (3-methyl-4-oxo-4H-[1]naphthylidenaminooxy)-acetic acid
• 英文别名: (3-Methyl-4-oxo-4H-[1]naphthylidenaminooxy)-essigsaeure；2-[(E)-(3-methyl-4-oxonaphthalen-1-ylidene)amino]oxyacetic acid
• CAS: 6146-99-2
• 化学式: C₁₃H₁₁NO₄
• 分子量: 245.235
• InChiKey: JBOOHWBSLUXBQW-SDNWHVSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  76
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  甲萘醌 在 乙醇 、 氨基羟基乙酸 作用下， 生成 (3-methyl-4-oxo-4H-[1]naphthylidenaminooxy)-acetic acid
  参考文献：
  名称：

  45. 2-甲基萘水溶性衍生物的制备

  摘要：

  DOI：

  10.1039/jr9480000182

文献信息

• Prodrugs containing novel bio-cleavable linkers
  申请人：Satyam Apparao

  公开号：US20060046967A1

  公开（公告）日：2006-03-02

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了公式(I)的化合物或其药用可接受的盐。本发明还提供了包含一个或多个公式I的化合物或其中间体以及一个或多个药用可接受的载体、车辆或稀释剂的药物组合物。本发明进一步提供了包括制备方法和使用方法在内的前药，包括释放一氧化氮的前药、双前药和相互前药，由公式I的化合物组成。
• [EN] NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS<br/>[FR] PROMÉDICAMENTS D'AGENTS THÉRAPEUTIQUES LIBÉRANT DE L'OXYDE NITRIQUE
  申请人：SATYAM APPARAO

  公开号：WO2014111957A1

  公开（公告）日：2014-07-24

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the preparation of these nitric oxide releasing prodrugs, to pharmaceutical compositions containing them and to methods of using these prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其中所述药物或治疗剂至少含有一个羧酸基团。发明还涉及制备这些一氧化氮释放前药的方法，包含它们的药物组合物以及使用这些前药的方法。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Solvent systems for pharmaceutical agents
  申请人：——

  公开号：US20020102280A1

  公开（公告）日：2002-08-01

  The invention provides compositions, solvent systems, and methods for solubilizing compounds which are otherwise difficult to solubilize. The invention involves the use of a structured fluid (e.g. a liquid crystalline phase, an L1 phase, an L2 phase, an L3 phase, an emulsion, or a microemulsion), comprising a polar solvent, a lipid or a surfactant, and an essential oil or a dissolution/solubilization agent.

  这项发明提供了用于溶解那些通常难以溶解的化合物的组合物、溶剂系统和方法。该发明涉及使用结构化流体（例如液晶相、L1相、L2相、L3相、乳化液或微乳化液），其中包括极性溶剂、脂质或表面活性剂以及精油或溶解/溶解剂。
• [EN] BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS AND METHODS OF PREPARATION AND USE THEREOF<br/>[FR] DÉRIVÉS BIGUANIDINE D'AGENTS THÉRAPEUTIQUES, ET PROCÉDÉS DE PRÉPARATION ET MÉTHODES D'UTILISATION CORRESPONDANTS
  申请人：PRIMETIME LIFE SCIENCES LLC

  公开号：WO2019050850A1

  公开（公告）日：2019-03-14

  The invention includes biguanidine derivatives of therapeutic agents of Formula IA or Formula IB including pharmaceutically acceptable, prodrugs, metabolites and isomers thereof. The invention also provides methods of preparation and use of these compounds for treating and/or preventing a wide variety of disease conditions and disorders. The invention also includes pharmaceutical compositions, preparation of prodrugs, and mutual prodrugs comprised of the constituent compounds of Formula IA, Formula IB Formula IC and Formula ID.

  该发明涵盖了治疗剂的大叶胍衍生物，包括公认的药用剂、前药、代谢物和其同分异构体的化合物，其化学式为IA或IB。该发明还提供了制备和使用这些化合物的方法，用于治疗和/或预防各种疾病和疾病状态。该发明还包括制药组合物、前药的制备以及由化合物IA、IB、IC和ID的组成物所组成的相互前药。